AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22519543 — intervention group
Group type: COMPARATOR
Intervention: Oral pentoxifylline (control)
Number of subjects: 24
Study 20188364 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified urinary FSH
Number of subjects: 0
Study 20188364 — intervention group
Group type: COMPARATOR
Intervention: Recombinant FSH
Number of subjects: 0
Study 17919374 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric and hypo-nitrogen parenteral nutrition (PN) with 18 (range 16-20) kcal x kg(‐1) x d(‐1) and nitrogen 0.10 (0.09-0.11) g x kg(‐1) x d(‐1)
Number of subjects: 120
Study 17919374 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric and hypo-nitrogen parenteral nutrition (PN)
Number of subjects: 120
Study 17919374 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving PN with 30 (28-32) kcal x kg(‐1) x d(‐1) and nitrogen 0.20 (0.19-0.21) g x kg(‐1) x d(‐1)
Number of subjects: 120
Study 17919374 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study 16030079 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week individualized home-based moderate-intensity exercise programme
Number of subjects: 79
Study 16030079 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 79
Study 12140028 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrectomy
Number of subjects: 7
Study 12140028 — intervention group
Group type: COMPARATOR
Intervention: Untreated fellow eye
Number of subjects: 7
Study 10221413 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem (0.5 g/8 h)
Number of subjects: 161
Study 10221413 — intervention group
Group type: COMPARATOR
Intervention: Imipenem/cilastatin (0.5 g/6 h)
Number of subjects: 161
Study 8563365 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-generated reminder system for diabetes care guidelines
Number of subjects: 35
Study 8563365 — intervention group
Group type: COMPARATOR
Intervention: Nonspecific report (control group)
Number of subjects: 35
Study 8563365 — intervention group
Group type: EXPERIMENTAL
Intervention: Encounter forms used by the system
Number of subjects: 35
Study 8563365 — intervention group
Group type: COMPARATOR
Intervention: No encounter forms used
Number of subjects: 35
Study 2353713 — intervention group
Group type: EXPERIMENTAL
Intervention: Representational figures (arrow, house, face)
Number of subjects: 30
Study 2353713 — intervention group
Group type: COMPARATOR
Intervention: Nonrepresentational figures (geometric shapes)
Number of subjects: 30
Study 31349348 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased time to hemostasis
Number of subjects: 680
Study 28385445 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital impressions with stereophotogrammetry
Number of subjects: 18
Study 28385445 — intervention group
Group type: COMPARATOR
Intervention: Traditional impressions
Number of subjects: 18
Study 26521190 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mg furosemide with HSS
Number of subjects: 42
Study 26521190 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg furosemide with HSS
Number of subjects: 42
Study 26521190 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg furosemide with HSS
Number of subjects: 42
Study 23480923 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral midazolam (0.5mg/kg) and ketamine (5mg/kg)
Number of subjects: 60
Study 23480923 — intervention group
Group type: COMPARATOR
Intervention: Oral midazolam (0.5mg/kg), acetaminophen (10mg/kg), and codeine (1mg/kg)
Number of subjects: 60
Study 22258912 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-hour psychoeducational group therapy
Number of subjects: 91
Study 22258912 — intervention group
Group type: COMPARATOR
Intervention: Standard care (no group therapy)
Number of subjects: 91
Study 19267777 — intervention group
Group type: EXPERIMENTAL
Intervention: MMF (2 g/day)
Number of subjects: 25
Study 19267777 — intervention group
Group type: EXPERIMENTAL
Intervention: SRL (15 mg loading dose, 5 mg for 7 days followed by 2 mg/day)
Number of subjects: 25
Study 19267777 — intervention group
Group type: EXPERIMENTAL
Intervention: PRED dose reduction
Number of subjects: 25
Study 19267777 — intervention group
Group type: EXPERIMENTAL
Intervention: TAC drug exposure
Number of subjects: 25
Study 19267777 — intervention group
Group type: EXPERIMENTAL
Intervention: SRL drug exposure
Number of subjects: 25
Study 17127027 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation
Number of subjects: 12
Study 17127027 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation
Number of subjects: 12
Study 15309009 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 2231
Study 11593835 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored implementation strategies for GPs
Number of subjects: 192
Study 11593835 — intervention group
Group type: COMPARATOR
Intervention: Dissemination alone (control group)
Number of subjects: 192
Study 9181425 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality assessment tool developed using Delphi technique
Number of subjects: 8
Study 9181425 — intervention group
Group type: COMPARATOR
Intervention: Quality assessment tool
Number of subjects: 8
Study 7940710 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose oral acyclovir (800 mg 4 times a day) for 3 months
Number of subjects: 143
Study 7940710 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ganciclovir (5 mg/kg twice a day for 14 days) followed by high dose oral acyclovir for 3 months
Number of subjects: 143
Study 3207788 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulus categorization (length of letter strings)
Number of subjects: 7
Study 30238292 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-incarceration services utilization
Number of subjects: 168
Study 30238292 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug use
Number of subjects: 168
Study 30238292 — intervention group
Group type: EXPERIMENTAL
Intervention: Health services utilization
Number of subjects: 168
Study 30238292 — intervention group
Group type: EXPERIMENTAL
Intervention: High rates of health services use
Number of subjects: 168
Study 28505217 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined patient decision aid and patient navigation
Number of subjects: 265
Study 28505217 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 265
Study 26081985 — intervention group
Group type: EXPERIMENTAL
Intervention: AmBisome 10 mg/kg day one (single dose)
Number of subjects: 160
Study 26081985 — intervention group
Group type: EXPERIMENTAL
Intervention: AmBisome 10 mg/kg day one and AmBisome 5 mg/kg day three (two doses)
Number of subjects: 160
Study 26081985 — intervention group
Group type: EXPERIMENTAL
Intervention: AmBisome 10 mg/kg day one, and AmBisome 5 mg/kg days three and seven (three doses)
Number of subjects: 160
Study 26081985 — intervention group
Group type: COMPARATOR
Intervention: AmBisome 3 mg/kg/d for 14 days
Number of subjects: 160
Study 26081985 — intervention group
Group type: EXPERIMENTAL
Intervention: Shortest course AmBisome regimen found to be non‐inferior in terms of EFA to the 14‐day control arm in STEP 1
Number of subjects: 160
Study 24083734 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyogenic liver abscess (PLA)
Number of subjects: 1987
Study 24083734 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1987
Study 24083734 — intervention group
Group type: EXPERIMENTAL
Intervention: PLA group
Number of subjects: 1987
Study 24083734 — intervention group
Group type: EXPERIMENTAL
Intervention: PLA group within the first year after diagnosis
Number of subjects: 1987
Study 24083734 — intervention group
Group type: EXPERIMENTAL
Intervention: PLA group more than one year after diagnosis
Number of subjects: 1987
Study 21214352 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling collar (CC)
Number of subjects: 8
Study 21214352 — intervention group
Group type: COMPARATOR
Intervention: No collar (NC)
Number of subjects: 8
Study 18442788 — intervention group
Group type: EXPERIMENTAL
Intervention: Dzherelo (50 drops twice per day)
Number of subjects: 40
Study 18442788 — intervention group
Group type: COMPARATOR
Intervention: Control (ATT: Isoniazid, Rimfapicin, Pyrazinamide, Streptomycin, Ethambutol)
Number of subjects: 40
Study 17305200 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive career-oriented group counseling
Number of subjects: 80
Study 17305200 — intervention group
Group type: COMPARATOR
Intervention: Nontreated group (control)
Number of subjects: 80
Study 14700111 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac 100 mg 30-45 minutes preoperatively
Number of subjects: 157
Study 14700111 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo 30-45 minutes preoperatively and diclofenac 100 mg at induction
Number of subjects: 157
Study 14700111 — intervention group
Group type: COMPARATOR
Intervention: Placebo 30-45 minutes preoperatively
Number of subjects: 157
Study 10906499 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclessa (desogestrel/ethinyl estradiol)
Number of subjects: 4200
Study 10906499 — intervention group
Group type: COMPARATOR
Intervention: Ortho‐Novum 7/7/7 (norethindrone/ethinyl estradiol)
Number of subjects: 4200
Study 8796933 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 1421679 — intervention group
Group type: EXPERIMENTAL
Intervention: Velnacrine 450 mg/d
Number of subjects: 24
Study 1421679 — intervention group
Group type: EXPERIMENTAL
Intervention: Velnacrine 300 mg/d
Number of subjects: 24
Study 1421679 — intervention group
Group type: EXPERIMENTAL
Intervention: Velnacrine 225 mg/d
Number of subjects: 24
Study 1421679 — intervention group
Group type: COMPARATOR
Intervention: Velnacrine 25 mg, 50 mg, 100 mg (twice daily)
Number of subjects: 24
Study 1421679 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 3900296 — intervention group
Group type: EXPERIMENTAL
Intervention: Primidone
Number of subjects: 22
Study 3900296 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 30419103 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive 3-month program for long-term self-management of COPD delivered by trained COPD nurses (n=120)
Number of subjects: 240
Study 30419103 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=120) including transition support for 30 days after discharge
Number of subjects: 240
Study 30419103 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive 3-month program for long-term self-management of COPD
Number of subjects: 240
Study 30419103 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 240
Study 26809849 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patches (5-week supply: 3 weeks of 21 mg, 1 week of 14 mg, 1 week of 7 mg)
Number of subjects: 1000
Study 26809849 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nicotine patches or other intervention)
Number of subjects: 1000
Study 26809849 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patches (5-week supply)
Number of subjects: 1000
Study 26222318 — intervention group
Group type: EXPERIMENTAL
Intervention: Linaclotide 145 μg
Number of subjects: 483
Study 26222318 — intervention group
Group type: EXPERIMENTAL
Intervention: Linaclotide 290 μg
Number of subjects: 483
Study 26222318 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 483
Study 24146767 — intervention group
Group type: EXPERIMENTAL
Intervention: IMPLEMENT intervention (active implementation of guideline recommendations plus standard dissemination)
Number of subjects: 0
Study 24146767 — intervention group
Group type: COMPARATOR
Intervention: Standard dissemination alone
Number of subjects: 0
Study 20952160 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical release by fasciectomy or dermofasciectomy
Number of subjects: 154
Study 18469422 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone call reminder for re-enrollment
Number of subjects: 1209
Study 18469422 — intervention group
Group type: COMPARATOR
Intervention: Usual care (postcard reminder)
Number of subjects: 1209
Study 16532436 — intervention group
Group type: EXPERIMENTAL
Intervention: TPZ, cisplatin, and 5-fluorouracil (5-FU)
Number of subjects: 62
Study 16532436 — intervention group
Group type: COMPARATOR
Intervention: cisplatin and 5-fluorouracil (5-FU) without TPZ
Number of subjects: 62
Study 16532436 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 62
Study 15228820 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-anesthesia outpatient consultation clinic 1 to 2 weeks prior to surgery
Number of subjects: 40
Study 15228820 — intervention group
Group type: COMPARATOR
Intervention: Pre-anesthetic assessment on the evening before surgery
Number of subjects: 40
Study 11199703 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorine dioxide-containing mouthrinse
Number of subjects: 31
Study 11199703 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (control)
Number of subjects: 31
Study 9091253 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-D FSE imaging
Number of subjects: 0
Study 9091253 — intervention group
Group type: COMPARATOR
Intervention: 2-D imaging
Number of subjects: 0
Study 8155115 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser scalpel
Number of subjects: 40
Study 8155115 — intervention group
Group type: COMPARATOR
Intervention: Conventional scalpel
Number of subjects: 40
Study 3524474 — intervention group
Group type: EXPERIMENTAL
Intervention: PEP mask with forced expiratory coughing
Number of subjects: 0
Study 3524474 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy
Number of subjects: 0
Study 28526995 — intervention group
Group type: EXPERIMENTAL
Intervention: Two cycles of PRGF-Endoret (TC group)
Number of subjects: 90
Study 28526995 — intervention group
Group type: COMPARATOR
Intervention: One cycle of PRGF-Endoret (OC group)
Number of subjects: 90
Study 27903339 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-directed hemodynamic management group (G group, n=45)
Number of subjects: 90
Study 27903339 — intervention group
Group type: COMPARATOR
Intervention: Experience anesthesia group (group E, n=45)
Number of subjects: 90
Study 27903339 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-directed hemodynamic management group (G group)
Number of subjects: 90
Study 24794140 — intervention group
Group type: EXPERIMENTAL
Intervention: Detectable cTnI levels at both time points (≥0.01 µg/L)
Number of subjects: 2514
Study 24794140 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent elevation of either or both cardiac biomarkers (cTnI and NT-proBNP) at baseline and 3 months
Number of subjects: 2514
Study 24794140 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated measurements of both cardiac biomarkers simultaneously
Number of subjects: 2514
Study 23061619 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly feedback on ventilator care bundle (VCB) compliance
Number of subjects: 2
Study 20102886 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine
Number of subjects: 535
Study 18612730 — intervention group
Group type: EXPERIMENTAL
Intervention: Training the Eye: Improving the Art of Physical Diagnosis (eight paired sessions of art observation exercises)
Number of subjects: 24
Study 15785019 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 232
Study 15785019 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 232
Study 11336939 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% once daily
Number of subjects: 33
Study 11336939 — intervention group
Group type: COMPARATOR
Intervention: Brimonidine 0.2% twice daily
Number of subjects: 33
Study 9210542 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive end-expiratory pressure at 30 cm H2O
Number of subjects: 15
Study 9210542 — intervention group
Group type: COMPARATOR
Intervention: Baseline airway pressure (0 cm H2O)
Number of subjects: 15
Study 7963789 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine Contin 100 mg every 12 hr
Number of subjects: 24
Study 7963789 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine Contin 200 mg every 12 hr
Number of subjects: 24
Study 7963789 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine Contin 300 mg every 12 hr
Number of subjects: 24
Study 7963789 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen plus codeine (600 mg/60 mg) every 6 hr
Number of subjects: 24
Study 7963789 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine Contin 150 mg every 12 hr
Number of subjects: 24
Study 3039842 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (20 mg per day)
Number of subjects: 205
Study 3039842 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 205
Study 29750977 — intervention group
Group type: EXPERIMENTAL
Intervention: HD-tDCS (1.5 mA for 25 minutes per day for two weeks)
Number of subjects: 31
Study 29750977 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 31
Study 29750977 — intervention group
Group type: EXPERIMENTAL
Intervention: HD-tDCS
Number of subjects: 31
Study 27829573 — intervention group
Group type: COMPARATOR
Intervention: Usual care delivered by a local rural Nurse Practitioner (NP)
Number of subjects: 0
Study 27829573 — intervention group
Group type: EXPERIMENTAL
Intervention: Local NP and an urban-based Physical Therapist (PT) joining via telehealth
Number of subjects: 0
Study 27829573 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face services by a PT traveling to the community
Number of subjects: 0
Study 23814135 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischaemic preconditioning (RIPC)
Number of subjects: 30
Study 23814135 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 30
Study 21220619 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.7-mg DEX implant
Number of subjects: 229
Study 21220619 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.35-mg DEX implant
Number of subjects: 229
Study 21220619 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 229
Study 19321584 — intervention group
Group type: EXPERIMENTAL
Intervention: High milk consumption (4 x 236 mL/d)
Number of subjects: 0
Study 19321584 — intervention group
Group type: COMPARATOR
Intervention: Low milk consumption (1 x 236 mL/d)
Number of subjects: 0
Study 19321584 — intervention group
Group type: EXPERIMENTAL
Intervention: High milk consumption
Number of subjects: 0
Study 17042662 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (600 mg BID orally, 4 doses)
Number of subjects: 20
Study 17042662 — intervention group
Group type: COMPARATOR
Intervention: Standard intravenous fluid hydration
Number of subjects: 20
Study 12772815 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine Purite and bimatoprost (brimP/bim)
Number of subjects: 28
Study 12772815 — intervention group
Group type: COMPARATOR
Intervention: Timolol gel-forming solution and latanoprost (tim/latan)
Number of subjects: 28
Study 10942479 — intervention group
Group type: EXPERIMENTAL
Intervention: 17beta-estradiol
Number of subjects: 34
Study 10942479 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 9425384 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal prongs
Number of subjects: 121
Study 9425384 — intervention group
Group type: COMPARATOR
Intervention: Nasopharyngeal catheters
Number of subjects: 121
Study 8218507 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation training (10 sessions over 8 weeks)
Number of subjects: 16
Study 8218507 — intervention group
Group type: COMPARATOR
Intervention: Symptom Monitoring (control group)
Number of subjects: 16
Study 3067105 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostacyclin sodium (2.5-5.0 ng/kg/min) administered intravenously once daily during 2 weeks in 6-hour infusions
Number of subjects: 30
Study 3067105 — intervention group
Group type: COMPARATOR
Intervention: Placebo (glycine buffer) administered intravenously once daily during 2 weeks in 6-hour infusions
Number of subjects: 30
Study 3067105 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostacyclin sodium
Number of subjects: 30
Study 28754504 — intervention group
Group type: EXPERIMENTAL
Intervention: Health messaging intervention focused on provider communication about vaccination for HPV vaccine.
Number of subjects: 2476
Study 28754504 — intervention group
Group type: EXPERIMENTAL
Intervention: Health messaging intervention focused on provider communication about vaccination for influenza vaccine.
Number of subjects: 2476
Study 28494175 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmapheresis (supportive treatments + plasmapheresis)
Number of subjects: 29
Study 28494175 — intervention group
Group type: COMPARATOR
Intervention: Supportive treatments (Control group)
Number of subjects: 29
Study 26241316 — intervention group
Group type: EXPERIMENTAL
Intervention: Approach avoid training (real)
Number of subjects: 588
Study 26241316 — intervention group
Group type: COMPARATOR
Intervention: Approach avoid training (sham)
Number of subjects: 588
Study 26241316 — intervention group
Group type: EXPERIMENTAL
Intervention: General identity training (real)
Number of subjects: 588
Study 26241316 — intervention group
Group type: COMPARATOR
Intervention: General identity training (sham)
Number of subjects: 588
Study 26241316 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized identity training (real)
Number of subjects: 588
Study 26241316 — intervention group
Group type: COMPARATOR
Intervention: Personalized identity training (sham)
Number of subjects: 588
Study 23590163 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing nature scenes (composed of trees, grass, fields)
Number of subjects: 0
Study 23590163 — intervention group
Group type: COMPARATOR
Intervention: Viewing built environments (composed of man‐made, urban scenes lacking natural characteristics)
Number of subjects: 0
Study 23590163 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing nature scenes
Number of subjects: 0
Study 21420417 — intervention group
Group type: EXPERIMENTAL
Intervention: ACWY-TT co-administered with DTaP-HBV-IPV/Hib
Number of subjects: 793
Study 19294861 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese medicinal formulae with immune regulation effects (group one)
Number of subjects: 60
Study 19294861 — intervention group
Group type: COMPARATOR
Intervention: Random Chinese medicinal formulae (control group)
Number of subjects: 60
Study 20153489 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (7-week endurance-type exercise at 65%-80% of maximum heart rate)
Number of subjects: 70
Study 16048220 — intervention group
Group type: EXPERIMENTAL
Intervention: Urgotul dressing
Number of subjects: 91